



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/714,079
				Filing Date	November 14, 2003
				First Named Inventor	Liise-anne Pirofski
				Art Unit	1645
				Examiner Name	Albert Mark Navarro
Sheet	1	of	3	Attorney Docket Number	ABX-AE1 CON

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
W		4,399,216	08/16/1983	Axel, et al.	
		4,510,245	04/09/1985	Cousens, et al.	
		4,634,665	01/06/1987	Axel, et al.	
		4,740,461	04/26/1988	Kaufman	
		4,912,040	03/27/1990	Kaufman, et al.	
		4,959,455	09/25/1990	Clark, et al.	
		4,968,615	11/06/1990	Koszinowski, et al.	
		5,168,062	12/01/1992	Stinski	
		5,179,017	01/12/1993	Axel, et al.	
		5,741,957	04/21/1998	Deboer, et al.	
		5,750,172	05/12/1998	Meade, et al.	
		5,756,887	05/26/1998	Denman, et al.	
		5,827,690	10/27/1998	Meade, et al.	
		5,916,771	06/29/1999	Hori, et al.	
		5,939,598	08/17/1999	Kucheralapati, et al.	
		5,985,615	11/16/1999	Jakobovits, et al.	
		5,998,209	12/07/1999	Jakobovits, et al.	
		6,075,181	06/13/2000	Kucheralapati, et al.	
		6,091,001	07/18/2000	Jakobovits, et al.	
		6,114,598	09/05/2000	Kucheralapati, et al.	
		6,130,364	10/10/2000	Jakobovits, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
W		EP 0 216 846	01/10/1990			
		EP 0 256 055	08/28/1991			
		EP 0 323 997	04/21/1993			
		EP 0 338 841	03/22/1995			
		WO 91/10741	07/25/1991			
		WO 94/02602	02/03/1994			
		WO 96/34096	10/31/1996			
		WO 96/33735	10/31/1996			
		WO 98/16654	04/23/1998			
		WO 98/24893	06/11/1998			
		WO 98/50433	11/12/1998			
		WO 99/45031	09/10/1999			
Examiner Signature	MARK NAVARRO			Date Considered	2/6/06	

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/714,079
				Filing Date	November 14, 2003
				First Named Inventor	Liise-anne Pirofski
				Art Unit	1645
				Examiner Name	Albert Mark Navarro
Sheet	2	of	3	Attorney Docket Number	ABX-AE1 CON

~	WO 99/53049	10/21/1999		
~	WO 00/09560	02/24/2000		
~	WO 00/037504	06/29/2000		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
~		Abadi, J. et al., "Human Antibodies Elicited by a Pneumococcal Vaccine Express Idiotype Determinants Indicative of V _H 3 Gene Segment Usage," <i>J. Infect. Dis.</i> 178:707-716 (1998)		
~		Bowie, J.U., et al., "A Method to Identify Protein Sequences That Fold Into a Known Three-Dimensional Structure," <i>Science</i> . 253:164-170 (1991)		
~		Chothia, C. & Lesk, A.M., "Canonical Structures for the Hypervariable Regions of Immunoglobulins," <i>J. Mol. Biol.</i> 196:901-917 (1987)		
~		Chothia, C., et al., "Conformations of Immunoglobulin Hypervariable Regions," <i>Nature</i> 342:877-883 (1989)		
~		Green, L.L. & Jakobovits, A., "Regulation of B Cell development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes," <i>J. Exp. Med.</i> 188:483-495 (1998)		
~		Green, L.L., et al., "Antigen-Specific Human Monoclonal Antibodies from Mice Engineered with Human Lg Heavy and Light Chain Yacs," <i>Nature Genet.</i> 7:13-21 (1994)		
~		Holliger, P., et al., "Diabodies": Small Bivalent and Bispecific Antibody Fragments," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:6444-6448 (1993)		
~		Johnson, G & Wu, T.T., "Kabat Database and its Applications: Future Directions," <i>Nucl. Acids Res.</i> 29:205-206 (2001)		
~		Kaufman, R.J. and Sharp, P.A., "Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene," <i>J. Mol. Biol.</i> 159:601-621 (1982)		
~		Kostelny, S.A., et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers," <i>J. Immunol.</i> 148:1547-1553 (1992)		
~		McCormick, L.L., et al., "Bispecific Antibodies Overcome the Opsonin-Receptor Mismatch of Cystic Fibrosis In Vitro: Restoration of Neutrophil-Mediated Phagocytosis and Killing of <i>Pseudomonas aeruginosa</i> ," <i>J Immunol.</i> 158:3474-3482 (1997)		
~		Mendez, M.J., et al., "Functional Transplant Of Megabase Human Immunoglobulin Loci Recapitulates Human Antibody Response in Mice," <i>Nat. Genet.</i> 15, pp. 146-156 (1997)		
~		Mukherjee, J. et al., "Molecular Characterization of the Humoral Responses to <i>Cryptococcus</i>		

Examiner Signature	MARK NAVARRO	Date Considered	2/6/06
--------------------	--------------	-----------------	--------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/714,079
				Filing Date	November 14, 2003
				First Named Inventor	Liise-anne Pirofski
				Art Unit	1645
				Examiner Name	Albert Mark Navarro
Sheet	3	of	3	Attorney Docket Number	ABX-AE1 CON

~		<i>neoformans</i> Infection and Glucuronoxylomannan-Tetanus Toxoid Conjugate Immunization," <i>J. Exp. Med.</i> 177:1105-1116 (1993)	
~		Pirofski, L., et al., "Analysis of Human Monoclonal Antibodies Elicited by Vaccination with a <i>Cryptococcus neogormans</i> Glucuronoxylomannan Capsular Polysaccharide Vaccine," <i>Infect. Immun.</i> 63:3005-3014 (1995) and <i>Infect. Immun.</i> 68:1820-1826 (2000)	
~		Russell, N.D., et al., "Production of Protective Human Antipneumococcal Antibodies by Transgenic Mice with Human Immunoglobulin Loci," <i>Infection Immunity</i> 68:1820-1826 (2000)	
~		Russell, N.D., et al., A Tale of Two Pathogens: Human Antibody Immunity to <i>Cryptococcus neoformans</i> and <i>Streptococcus pneumoniae</i> ," <i>Einstein Quart. J. Biol. Med.</i> 15:148-157 (1998)	
~		Songsilvilai, S. & Lachmann, P.C., "Bispecific antibody: a tool for diagnosis and treatment of disease," <i>Clin. Exp. Immunol.</i> 79:315-321 (1990)	
~		Thornton, J.M., et al., "Prediction of progress at last," <i>Nature</i> 354:105-106 (1991)	
~		Traunecker, A., et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>EMBO J.</i> 10:3655-3659 (1991)	
~		Traunecker, A., et al., "Janusin: New molecular design for bispecific reagents," <i>Int. J. Cancer Suppl.</i> 7:51-52 (1992)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	MARK NAVARRO	Date Considered	2/6/06
--------------------	--------------	-----------------	--------